On Friday 07/05/2024 the closing price of the Centene Corp. share was $66.37 on BTT.
Compared to the opening price on Friday 07/05/2024 on BTT of $66.37, this is a gain of 0.00%.
Centene Corp.'s market capitalization is $35.64 B by 533.66 M shares outstanding.
Is Centene stock a Buy, Sell or Hold?
Centene stock has received a consensus rating of buy. The average rating score is and is based on 35 buy ratings, 21 hold ratings, and 1 sell ratings.What was the 52-week low for Centene stock?
The low in the last 52 weeks of Centene stock was 60.84. According to the current price, Centene is 109.09% away from the 52-week low.What was the 52-week high for Centene stock?
The high in the last 52 weeks of Centene stock was 81.41. According to the current price, Centene is 81.53% away from the 52-week high.What are analysts forecasts for Centene stock?
The 57 analysts offering price forecasts for Centene have a median target of 89.56, with a high estimate of 115.00 and a low estimate of 71.00. The median estimate represents a 74.11 difference from the last price of 66.37.Centene Stock Snapshot
66.34
Bid
16.00
Bid Size
66.41
Ask
17.00
Ask Size
7/5/2024
Date
3:59 PM
Time
96,177.00
Volume
66.74
Prev. Close
66.37
Open
35.64 B
Market Cap in USD
533.66 M
Number of Shares
65.72
Day Low
66.44
Day High
66.37
60.84
52 Week Low
81.41
52 Week High
66.37
0.00
Dividend in USD
0.00
Dividend Yield
14.99
P/E Ratio
98.96
Free Float in %
4.97
EPS in USD
48.35
Book Value per Share in USD
14.76
Cash Flow per Share in USD
Centene News More News
Historical Prices for Centene
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Centene Analyst Data
Total Analysts: 57
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 71.00
Median: 89.56
Highest: 115.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Centene Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/21/24 | Oppenheimer & Co. Inc. | Maintained Buy | $110 | |||
| 06/12/24 | Cantor Fitzgerald | Maintained Buy | $90 | |||
| 05/30/24 | Stephens Inc. | Maintained Hold | $83 | |||
| 05/30/24 | Baird Patrick & Co | Maintained Hold | $83 | |||
| 05/02/24 | Barclays Capital | Maintained Buy | $104 | |||
| 04/30/24 | Deutsche Bank | Maintained Hold | $82 | |||
| 04/29/24 | Oppenheimer & Co. Inc. | Maintained Buy | $110 | |||
| 04/15/24 | Wells Fargo & Co | Maintained Buy | $93 | |||
| 04/08/24 | Wells Fargo & Co | Maintained Buy | $89 | |||
| 04/04/24 | Cantor Fitzgerald | Maintained Buy | $90 | |||
| 03/25/24 | Stephens Inc. | Downgraded to Hold | $85 | |||
| 03/21/24 | Stephens Inc. | Downgraded to Hold | $85 | |||
| 03/20/24 | Wells Fargo & Co | Maintained Buy | $94 | |||
| 03/06/24 | Barclays Capital | Maintained Buy | $101 | |||
| 01/02/24 | Wells Fargo & Co | Upgraded to Buy | $90 | |||
| 12/21/23 | UBS | Maintained Hold | $79 | |||
| 12/15/23 | Cantor Fitzgerald | Maintained Buy | $90 | |||
| 12/13/23 | Wells Fargo & Co | Maintained Hold | $82 | |||
| 11/21/23 | Cantor Fitzgerald | Maintained Buy | $82 | |||
| 10/26/23 | Wells Fargo & Co | Maintained Hold | $74 | |||
| 10/09/23 | Jefferies & Company Inc. | Maintained Buy | $81 | |||
| 09/14/23 | Cantor Fitzgerald | Maintained Buy | $82 | |||
| 09/05/23 | Bank of America Merrill Lynch | Upgraded to Hold | $72 | |||
| 08/30/23 | Morgan Stanley | Downgraded to Hold | $73 | |||
| 07/31/23 | Oppenheimer & Co. Inc. | Maintained Buy | $110 | |||
| 07/31/23 | Barclays Capital | Maintained Buy | $85 | |||
| 07/14/23 | Morgan Stanley | Maintained Buy | $94 | |||
| 07/12/23 | Wolfe Research | Downgraded to Hold | ||||
| 07/11/23 | Mizuho | Maintained Hold | $76 | |||
| 07/07/23 | J.P. Morgan | Maintained Hold | $77 | |||
| 06/20/23 | UBS | Maintained Hold | $72 | |||
| 05/26/23 | Oppenheimer & Co. Inc. | Maintained Buy | $110 | |||
| 05/26/23 | Stephens Inc. | Maintained Buy | $87 | |||
| 04/26/23 | Stephens Inc. | Maintained Buy | $87 | |||
| 04/26/23 | Credit Suisse | Maintained Buy | $87 | |||
| 04/26/23 | Barclays Capital | Maintained Buy | $86 | |||
| 04/21/23 | Cantor Fitzgerald | Maintained Buy | $80 | |||
| 04/11/23 | Barclays Capital | Maintained Buy | $90 | |||
| 03/21/23 | Wells Fargo & Co | Maintained Hold | $71 | |||
| 03/09/23 | Morgan Stanley | Maintained Buy | $94 | |||
| 03/08/23 | Deutsche Bank | Downgraded to Hold | $79 | |||
| 02/28/23 | Mizuho | Maintained Hold | $80 | |||
| 02/23/23 | J.P. Morgan | Downgraded to Hold | $90 | |||
| 02/14/23 | Cowen and Company, LLC | Maintained Buy | $97 | |||
| 02/08/23 | Goldman Sachs | Maintained Hold | $74 | |||
| 02/08/23 | J.P. Morgan | Maintained Buy | $94 | |||
| 02/08/23 | Mizuho | Maintained Hold | $92 | |||
| 02/08/23 | Barclays Capital | Maintained Buy | $93 | |||
| 01/06/23 | J.P. Morgan | Maintained Buy | $98 | |||
| 12/19/22 | Credit Suisse | Maintained Buy | $106 |
Centene Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | 150,318 | 155,796 | 160,856 | 168,442 |
| Dividend | 0.00 | 1.25 | 0.00 | - |
| Dividend Yield (in %) | 0.00 % | 1.87 % | 0.00 % | - |
| EPS | 6.85 | 7.59 | 8.48 | 9.98 |
| P/E Ratio | 9.75 | 8.80 | 7.87 | 6.69 |
| EBIT | 3,691 | 4,012 | 4,529 | 5,636 |
| EBITDA | 4,549 | 4,882 | 5,491 | - |
| Net Profit | 3,603 | 3,769 | 4,090 | 4,227 |
| Net Profit Adjusted | 3,603 | 3,769 | 4,090 | 4,227 |
| Pre-Tax Profit | 4,457 | 4,676 | 5,126 | 5,636 |
| Net Profit (Adjusted) | 4,454 | 4,705 | 5,123 | - |
| EPS (Non-GAAP) ex. SOE | 5.81 | 6.42 | 7.34 | - |
| EPS (GAAP) | 5.95 | 6.49 | 7.52 | 9.23 |
| Gross Income | 29,070 | 28,296 | 28,668 | - |
| Cash Flow from Investing | 560 | -658 | -752 | -1,321 |
| Cash Flow from Operations | 2,578 | 4,931 | 5,247 | 5,995 |
| Cash Flow from Financing | -3,552 | -2,450 | -2,550 | -2,000 |
| Cash Flow per Share | 6.14 | 10.65 | 11.05 | - |
| Free Cash Flow | 1,900 | 4,208 | 4,546 | 4,816 |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | 51.10 | 57.25 | 61.99 | - |
| Net Debt | 1,016 | -1,386 | -2,922 | - |
| Research & Development Exp. | - | - | - | - |
| Capital Expenditure | 643 | 780 | 782 | 1,179 |
| Selling, General & Admin. Exp. | 12,146 | 12,606 | 13,500 | - |
| Shareholder’s Equity | 26,037 | 27,690 | 29,648 | 33,466 |
| Total Assets | 80,137 | 82,725 | 85,663 | 88,489 |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 18 | 18 | 18 | 19 | 19 |
| Average Estimate | 1.973 USD | 1.814 USD | 0.766 USD | 6.846 USD | 7.588 USD |
| Year Ago | 1.927 USD | 0.869 USD | 0.084 USD | 4.973 USD | - |
| Publish Date | 7/26/2024 | 10/25/2024 | 2/11/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 15 | 15 | 15 | 17 | 17 |
| Average Estimate | 36,593 USD | 36,398 USD | 36,878 USD | 150,318 USD | 155,796 USD |
| Year Ago | 37,608 USD | 38,042 USD | 39,460 USD | 153,999 USD | - |
| Publish Date | 7/26/2024 | 10/25/2024 | 2/11/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 153,999.00 | 144,547.00 | 125,982.00 | 111,115.00 | 74,639.00 | 60,116.00 | 48,382.00 |
| Change of sales in % | 6.54 | 14.74 | 13.38 | 48.87 | 24.16 | 24.25 | 19.15 |
| Gross profit on sales | - | - | - | - | - | - | - |
| Gross profit on sales change in % | - | - | - | - | - | - | - |
| Operating income | 3,615.00 | 3,859.00 | 3,488.00 | 3,734.00 | 2,137.00 | 1,879.00 | 1,218.00 |
| Operating income change in % | -6.32 | 10.64 | -6.59 | 74.73 | 13.73 | 54.27 | -18.20 |
| Income before tax | 3,598.00 | 1,962.00 | 1,813.00 | 2,773.00 | 1,782.00 | 1,368.00 | 1,134.00 |
| Income before tax change in % | 83.38 | 8.22 | -34.62 | 55.61 | 30.26 | 20.63 | -1.99 |
| Income after tax | 2,702.00 | 1,202.00 | 1,347.00 | 1,808.00 | 1,321.00 | 900.00 | 828.00 |
| Income after tax change in % | 124.79 | -10.76 | -25.50 | 36.87 | 46.78 | 8.70 | 47.33 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 59,942.00 | 54,301.00 | 52,738.00 | 43,881.00 | 28,302.00 | 19,878.00 | 14,979.00 |
| Long-term liabilities per share | - | - | - | - | - | - | - |
| Equity | 25,956.00 | 24,237.00 | 27,022.00 | 25,962.00 | 12,692.00 | 11,023.00 | 6,876.00 |
| Equity change in % | 7.41 | -10.22 | 3.97 | 105.35 | 14.97 | 59.37 | 16.20 |
| Balance sheet total | 85,898.00 | 78,538.00 | 79,760.00 | 69,843.00 | 40,994.00 | 30,901.00 | 21,855.00 |
| Balance sheet total change in % | 9.37 | -1.53 | 14.20 | 70.37 | 32.66 | 41.39 | 8.21 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 282.20 | 248.35 | 213.34 | 191.86 | 177.54 | 150.85 | 136.90 |
| P/E ratio (year end quote, basic EPS) | 14.99 | 39.71 | 36.12 | 19.23 | 20.01 | 25.53 | 21.53 |
| P/E ratio (year end quote, diluted EPS) | 14.99 | 39.71 | 36.12 | 19.23 | 20.01 | 25.53 | 21.53 |
| P/E ratio (year end quote) | 14.99 | 39.71 | 36.12 | 19.23 | 20.01 | 25.53 | 21.53 |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 30.08 | 30.63 | 33.59 | 36.90 | 30.62 | 35.33 | 31.34 |
| Debt ratio in % | 69.78 | 69.14 | 66.12 | 62.83 | 69.04 | 64.33 | 68.54 |
Centene Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| DeVeydt Wayne S | 06/29/2024 | 490.00 | 13,827.27 | n/a | Buy | No |
| LONDON SARAH | 06/22/2024 | 1,987.00 | 711,677.00 | 67.93 | Sell | No |
| KOSTER CHRISTOPHER | 06/22/2024 | 1,987.00 | 196,734.00 | 67.93 | Sell | No |
| SMITH SUSAN RAYE | 06/14/2024 | 5,984.00 | 60,839.00 | 68.93 | Sell | No |
| COUGHLIN CHRISTOPHER J | 05/13/2024 | 878.00 | n/a | 76.75 | Sell | No |
| FORD MONTE E | 05/13/2024 | 2,916.00 | 7,255.77 | n/a | Buy | No |
| Dallas H James | 05/13/2024 | 2,916.00 | 40,303.19 | n/a | Buy | No |
| EPPINGER FREDERICK H | 05/13/2024 | 4,861.00 | 351,072.66 | n/a | Buy | No |
| Robinson Lori Jean | 05/13/2024 | 2,916.00 | 14,371.00 | n/a | Buy | No |
| COUGHLIN CHRISTOPHER J | 05/13/2024 | 2,916.00 | 25,503.93 | n/a | Buy | No |
| Burdick Kenneth A | 05/13/2024 | 2,916.00 | 361,066.92 | n/a | Buy | No |
| Samuels Theodore R. II | 05/13/2024 | 2,916.00 | 12,910.98 | n/a | Buy | No |
| BLUME JESSICA L. | 05/13/2024 | 2,916.00 | 24,786.00 | n/a | Buy | No |
| DeVeydt Wayne S | 05/13/2024 | 2,916.00 | 13,337.27 | n/a | Buy | No |
| FASOLA KENNETH J | 05/12/2024 | 8,000.00 | 300,357.00 | 77.62 | Sell | No |
| Asher Andrew Lynn | 05/06/2024 | 6,559.00 | 469,647.48 | 75.14 | Sell | No |
| Asher Andrew Lynn | 04/25/2024 | 4,638.00 | 476,206.48 | 75.68 | Sell | No |
| CASSO KATIE | 03/31/2024 | 922.00 | 61,017.00 | 78.48 | Sell | No |
| Burdick Kenneth A | 03/30/2024 | 388.55 | 358,150.92 | n/a | Buy | No |
| DeVeydt Wayne S | 03/30/2024 | 420.93 | 10,421.27 | n/a | Buy | No |
| COUGHLIN CHRISTOPHER J | 03/30/2024 | 388.55 | 22,587.93 | n/a | Buy | No |
| Samuels Theodore R. II | 03/30/2024 | 323.79 | 9,994.98 | n/a | Buy | No |
| EPPINGER FREDERICK H | 03/30/2024 | 323.79 | 346,211.66 | n/a | Buy | No |
| KOSTER CHRISTOPHER | 03/14/2024 | 2,135.00 | 161,540.46 | 76.05 | Sell | No |
| LONDON SARAH | 03/14/2024 | 11,182.00 | 527,602.00 | 76.05 | Sell | No |
Centene Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Centene Corp. | 0.00 | 0.00 | USD |
| 2022 | Centene Corp. | 0.00 | 0.00 | USD |
| 2021 | Centene Corp. | 0.00 | 0.00 | USD |
| 2020 | Centene Corp. | 0.00 | 0.00 | USD |
| 2019 | Centene Corp. | 0.00 | 0.00 | USD |
| 2018 | Centene Corp. | 0.00 | 0.00 | USD |
| 2017 | Centene Corp. | 0.00 | 0.00 | USD |
| 2016 | Centene Corp. | 0.00 | 0.00 | USD |
| 2015 | Centene Corp. | 0.00 | 0.00 | USD |
| 2014 | Centene Corp. | 0.00 | 0.00 | USD |
| 2013 | Centene Corp. | 0.00 | 0.00 | USD |
| 2012 | Centene Corp. | 0.00 | 0.00 | USD |
| 2011 | Centene Corp. | 0.00 | 0.00 | USD |
| 2010 | Centene Corp. | 0.00 | 0.00 | USD |
| 2009 | Centene Corp. | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Centene Corp. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.973 USD | Q2 2024 Earnings Release | 07/26/2024 |
| Press Conference | - | 07/26/2024 | |
| Earnings Report | 1.814 USD | Q3 2024 Earnings Release | 10/25/2024 |
| Earnings Report | 0.766 USD | Q4 2024 Earnings Release | 02/11/2025 |
| Earnings Report | 2.477 USD | Q1 2025 Earnings Release | 04/29/2025 |
| Earnings Report | 2.188 USD | Q2 2025 Earnings Release | 07/29/2025 |
| Earnings Report | 1.936 USD | Q3 2025 Earnings Release | 10/28/2025 |
Centene Corp. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/14/2024 |
| Earnings Report | 2.173 USD | Q1 2024 Earnings Release | 04/26/2024 |
| Press Conference | - | - | 04/26/2024 |
Centene Profile
Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St.
Moody’s Daily Credit Risk Score
Centene Shareholder
| Owner | in % |
|---|---|
| Freefloat | 98.96 |
| The Vanguard Group, Inc. | 11.47 |
| Vanguard Group, Inc. (Subfiler) | 10.98 |
| Capital Research & Management Co. (World Investors) | 5.46 |
| Capital Research & Management Co. (World Investors) | 5.05 |
| Fidelity Management & Research Co. LLC | 4.95 |
| State Street Corp. | 4.39 |
| Wellington Management Co. LLP | 3.71 |
| Norges Bank (13F) | 3.35 |
| Government Pension Fund - Global (The) | 3.34 |
| Harris Associates LP | 3.18 |
| Vanguard Total Stock Market ETF | 3.16 |
| American Funds Fundamental Investors | 2.90 |
| Vanguard 500 Index Fund | 2.57 |
| BlackRock Fund Advisors | 2.43 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Centene Management
| Name | Job |
|---|---|
| Frederick H. Eppinger | Chairman |
| Katie N. Casso | Chief Accounting Officer, Senior VP & Controller |
| Anika Gardenhire | Chief Customer Experience Officer |
| Sarah McGinty London | Chief Executive Officer & Director |
| Andrew Lynn Asher | Chief Financial Officer & Executive Vice President |
| Wade A. Rakes | Chief Growth Officer |
| Alice Hm Chen | Chief Health Officer |
| Brian P. LeClaire | Chief Information Officer |
| Suzy DePrizio | Chief Marketing Officer & Senior Vice President |
| Susan Smith | Chief Operating Officer |
| Chan See Wing Arvan | Chief Operating Officer-International & Senior VP |
| Tanya McNally | Chief People Officer & Senior Vice President |
| Ashlee Knuckey | Chief Risk, Ethics & Compliance Officer |
| Kenneth A. Burdick | Director |
| David P. Thomas | Executive Vice President-Markets |
| Colin Toney | Executive Vice President-Mergers & Acquisitions |
| Christopher J. Coughlin | Independent Director |
| Lori J. Robinson | Independent Director |
| Wayne S. DeVeydt | Independent Director |
| Jessica L. Blume | Independent Director |
| Monte E. Ford | Independent Director |
| H. James Dallas | Independent Director |
| Theodore Rapp Samuels | Independent Director |
| Kenneth J. Fasola | President |
| Michael A. Carson | President-Medicare & CEO-Medicare |
| Christopher A. Koster | Secretary, Executive VP & General Counsel |
| Jennifer Gilligan | Senior VP-Finance & Investor Relations |
| Beau Garverick | Senior Vice President |
| Richard Fisher | Senior Vice President |
| Kevin J. Counihan | Senior Vice President-Products |
| Gerald Roberts | Vice President-Strategy & Business Development |